Pathogen inactivation technology: cleansing the blood supply
- 16 February 2005
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 257 (3), 224-237
- https://doi.org/10.1111/j.1365-2796.2005.01451.x
Abstract
The calculated residual infectious risk of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) from blood transfusion is extremely low. However, the risk of bacterial contamination remains and a variety of other agents including emerging viruses, protozoa and tick-borne agents threaten blood supplies and undermine public confidence in blood safety. Traditional methods of donor screening and testing have limited ability to further reduce disease transmission and cannot prevent an emerging infectious agent from entering the blood supply. Pathogen inactivation technologies have all but eliminated the infectious risks of plasma-derived protein fractions, but as yet no technique has proved sufficiently safe and effective for traditional blood components. Half-way technologies can reduce the risk of pathogen transmission from fresh frozen plasma and cryoprecipitate. Traditional methods of mechanical removal such as washing and filtration have limited success in reducing the risk of cell-associated agents, but methods aimed at sterilizing blood have either proved toxic to the cells or to the recipients of blood components. Several promising methods that target pathogen nucleic acid have recently entered clinical testing.Keywords
This publication has 67 references indexed in Scilit:
- Binding Affinities of Commonly Employed Sensitizers of Viral Inactivation¶Photochemistry and Photobiology, 2007
- Separation, Identification and Quantification of Riboflavin and its Photoproducts in Blood Products using High‐performance Liquid Chromatography with Fluorescence Detection: A Method to Support Pathogen Reduction Technology¶Photochemistry and Photobiology, 2004
- Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialBlood, 2004
- Riboflavin and UV‐Light Based Pathogen Reduction: Extent and Consequence of DNA Damage at the Molecular LevelPhotochemistry and Photobiology, 2004
- Oversight and Monitoring of Blood Safety in the United StatesVox Sanguinis, 1999
- Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator GroupTransfusion, 1992
- Erythropoietin for the Treatment of Porphyria Cutanea Tarda in a Patient on Long-Term HemodialysisThe New England Journal of Medicine, 1990
- Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitisJournal of Medical Virology, 1990
- Coincidental Appearance of LAV/HTLV-III Antibodies in Hemophiliacs and the Onset of the AIDS EpidemicThe New England Journal of Medicine, 1985
- IMMUNOLOGIC REACTIVITY IN MARROW GRAFT RECIPIENTS RECEIVING CYCLOSPORINE TO PREVENT GRAFT-VERSUS-HOST DISEASETransplantation, 1983